H3N2 Infection – Pipeline Review, H1 2016

$2,000

The report provides comprehensive information on the therapeutics under development for H3N2 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history …..

Total Pages: 107

Global Markets Direct’s, ‘H3N2 Infection - Pipeline Review, H1 2016’, provides an overview of the H3N2 Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H3N2 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H3N2 Infection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
- The report reviews pipeline therapeutics for H3N2 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved H3N2 Infection therapeutics and enlists all their major and minor projects
- The report assesses H3N2 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for H3N2 Infection

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
H3N2 Infection Overview 10
Therapeutics Development 11
Pipeline Products for H3N2 Infection - Overview 11
Pipeline Products for H3N2 Infection - Comparative Analysis 12
H3N2 Infection - Therapeutics under Development by Companies 13
H3N2 Infection - Therapeutics under Investigation by Universities/Institutes 15
H3N2 Infection - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
H3N2 Infection - Products under Development by Companies 19
H3N2 Infection - Products under Investigation by Universities/Institutes 21
H3N2 Infection - Companies Involved in Therapeutics Development 22
AIMM Therapeutics B.V. 22
Aphios Corporation 23
Crucell N.V. 24
CSL Limited 25
Glide Pharmaceutical Technologies Limited 26
ILiAD Biotechnologies, LLC 27
Inovio Pharmaceuticals, Inc. 28
Johnson & Johnson 29
Medicago Inc. 30
MedImmune, LLC 31
Mucosis B.V. 32
NanoViricides, Inc. 33
Novavax, Inc. 34
OPKO Health, Inc. 35
Sarepta Therapeutics, Inc. 36
Takeda Pharmaceutical Company Limited 37
Visterra, Inc. 38
Zydus Cadila Healthcare Limited 39
H3N2 Infection - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
APP-0205 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
APP-309 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Aspidasept - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
C-05 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CR-8020 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CR-9114 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
FluGEM - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Gamma-Flu - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
influenza [strain A/H3N2] vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
influenza [strain A/H3N2] vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
JNJ-872 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NVINF-1 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
NVINF-2 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pertussis [strain BPZE1] vaccine - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PNSIA-28 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
radavirsen - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules for RSV and Influenza A Infections - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
TXB-248 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
VIS-410 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
H3N2 Infection - Recent Pipeline Updates 90
H3N2 Infection - Dormant Projects 103
H3N2 Infection - Product Development Milestones 104
Featured News & Press Releases 104
Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 104
Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 104
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107

List of Tables
Number of Products under Development for H3N2 Infection, H1 2016 11
Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
H3N2 Infection - Pipeline by AIMM Therapeutics B.V., H1 2016 22
H3N2 Infection - Pipeline by Aphios Corporation, H1 2016 23
H3N2 Infection - Pipeline by Crucell N.V., H1 2016 24
H3N2 Infection - Pipeline by CSL Limited, H1 2016 25
H3N2 Infection - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016 26
H3N2 Infection - Pipeline by ILiAD Biotechnologies, LLC, H1 2016 27
H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 28
H3N2 Infection - Pipeline by Johnson & Johnson, H1 2016 29
H3N2 Infection - Pipeline by Medicago Inc., H1 2016 30
H3N2 Infection - Pipeline by MedImmune, LLC, H1 2016 31
H3N2 Infection - Pipeline by Mucosis B.V., H1 2016 32
H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2016 33
H3N2 Infection - Pipeline by Novavax, Inc., H1 2016 34
H3N2 Infection - Pipeline by OPKO Health, Inc., H1 2016 35
H3N2 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2016 36
H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 37
H3N2 Infection - Pipeline by Visterra, Inc., H1 2016 38
H3N2 Infection - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 39
Assessment by Monotherapy Products, H1 2016 40
Assessment by Combination Products, H1 2016 41
Number of Products by Stage and Target, H1 2016 43
Number of Products by Stage and Mechanism of Action, H1 2016 45
Number of Products by Stage and Route of Administration, H1 2016 47
Number of Products by Stage and Molecule Type, H1 2016 49
H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2016 90
H3N2 Infection - Dormant Projects, H1 2016 103

List of Figures
Number of Products under Development for H3N2 Infection, H1 2016 11
Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 40
Assessment by Combination Products, H1 2016 41
Number of Products by Targets, H1 2016 42
Number of Products by Stage and Targets, H1 2016 42
Number of Products by Mechanism of Actions, H1 2016 44
Number of Products by Stage and Mechanism of Actions, H1 2016 44
Number of Products by Top 10 Routes of Administration, H1 2016 46
Number of Products by Stage and Routes of Administration, H1 2016 46
Number of Products by Molecule Types, H1 2016 48
Number of Products by Stage and Molecule Types, H1 2016 48

Company Mentioned

AIMM Therapeutics B.V.
Aphios Corporation
Crucell N.V.
CSL Limited
Glide Pharmaceutical Technologies Limited
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Medicago Inc.
MedImmune, LLC
Mucosis B.V.
NanoViricides, Inc.
Novavax, Inc.
OPKO Health, Inc.
Sarepta Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
Visterra, Inc.
Zydus Cadila Healthcare Limited


LICENSE TYPE